Methods for Resensitizing p53-Null Cells to Cancer Chemotherapy

摘要

The present disclosure is directed to methods for treating patients who have been diagnosed with cancers having a TP53 mutation. Aspects of the disclosure can be implemented to determine a treatment course for patients who have been diagnosed with a cancer having a TP53 mutation by excluding pharmaceutical compounds based, at least in part, on a genetic profile of the cancer. Additionally, aspects of the disclosure can be implemented to mitigate the effects of TP53 mutations by targeting biological pathways such as the spindle assembly checkpoint (SAC) to enhance or otherwise improve the efficacy of certain FDA-approved compounds. For instance, an example implementation of the disclosure can include a method for treating a patient who has been diagnosed with a cancer having a TP53 mutation. Advantages of the embodiments disclosed herein can provide patients with improved treatment efficacy when using chemotherapies or by reducing exposure to chemotherapeutics that demonstrate lower efficacy based on the genetic profile of the cancer.